Business
-
According to Perrigo Company, which is partnered with Teva on a generic triamcinolone acetonide nasal spray, Teva has begun shipping the product. Perrigo developed the nasal spray, which is a generic equivalent of Sanofi’s Nasacort… Read more . . .
-
Sun Pharma Advanced Research Company (SPARC) has announced completion of Phase 3 studies for a new dry powder inhaler and its intention to launch a product based on the novel DPI in India by the… Read more . . .
-
Dry powder inhalation drug developer Savara Pharmaceuticals has graduated from the Austin Techonology Incubator (ATI) Bioscience Incubator, according to ATI. Savara, which was founded in 2007, is preparing for Phase 1 trials of its lead… Read more . . .
-
GlaxoSmithKline plans to expand its manufacturing facility in Mississauga, Ontario, in part to enable production of Relenza zanamivir dry powder for inhalation. The expansion is expected to create 70 new jobs. GSK will contribute more… Read more . . .
-
Respira Therapeutics has issued a press release to introduce its drug engine technology (DET) dry powder inhaler, which the company says “can be deployed and optimized in short test cycles with a wide range of… Read more . . .
-
University of Melbourne spin-off Otifex has reportedly raised $1.1 million for the development of a nasal spray to treat otitis media with effusion (OTE), in which viscous fluid builds up in the middle ear, potentially… Read more . . .
-
Reuters is reporting that the Swedish Medical Products Agency has approved a fluticasone/salmeterol DPI manufactured by Greek pharmaceutical company Elpen. The approval apparently took place in May 2011 but was not announced. The company has… Read more . . .
-
Generex Biotechnology has reached an agreement with Amarantus BioSciences regarding Generex’s RapidMist buccal aerosol delivery system. The RapidMist device is a modified metered dose inhaler that delivers the aerosol to the lining of the mouth… Read more . . .
-
Rigel Pharmaceuticals has said that it is raising approximately $130.4 million as the result of a stock offering involving 16.3 million new shares. The company says that it expects the offer to close on or… Read more . . .
-
Members of the Committee for Medicinal Products for Human Use (CHMP) have indicated that they would vote against approval of Pharmaxis’s marketing application for Bronchitol as a treatment for cystic fibrosis (CF). The CHMP took… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland